TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2510661

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg) + Propranolol (80 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 16219589

Group type: EXPERIMENTAL
Intervention: Chemoprevention (Tamoxifen or Raloxifene)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Non-participation in chemoprevention
Number of subjects: 51
Study: 31785779

Group type: EXPERIMENTAL
Intervention: Exposure to di (2‐ethylhexyl), butyl‐benzyl and di‐isobutyl phthalates (DEHP, BBzP, DiBP)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: DEHP, BBzP, and DiBP exposure
Number of subjects: 80
Study: 31622137

Group type: EXPERIMENTAL
Intervention: Self-rated health (SRH) with pasable
Number of subjects: 3261

Group type: COMPARATOR
Intervention: Self-rated health (SRH) with regular
Number of subjects: 3261
Study: 27096538

Group type: EXPERIMENTAL
Intervention: Combined therapy (sequential delivery of IPL and Nd:YAG laser)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Separated therapy (IPL followed by Nd:YAG treatment 3 days later)
Number of subjects: 24
Study: 26682290

Group type: EXPERIMENTAL
Intervention: Imiquimod cream 3.75% applied once daily until complete clearance or a maximum of 8 weeks
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Imiquimod cream 2.5% applied once daily until complete clearance or a maximum of 8 weeks
Number of subjects: 447

Group type: COMPARATOR
Intervention: Placebo applied once daily until complete clearance or a maximum of 8 weeks
Number of subjects: 447
Study: 22925000

Group type: EXPERIMENTAL
Intervention: Procalcitonin ultrasensitive-guided antibiotic treatment
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard stroke unit care
Number of subjects: 200
Study: 22048577

Group type: EXPERIMENTAL
Intervention: TCP alone
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: TCP + CA
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: TCP + CA + ORC
Number of subjects: 39
Study: 19536974

Group type: EXPERIMENTAL
Intervention: Recent RCTs of psychotherapy
Number of subjects: 0
Study: 16878192

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.2 mg/kg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 15238624

Group type: EXPERIMENTAL
Intervention: Endoscopic laser surgery
Number of subjects: 142

Group type: COMPARATOR
Intervention: Serial amnioreduction
Number of subjects: 142
Study: 11534893

Group type: EXPERIMENTAL
Intervention: Formoterol
Number of subjects: 0
Study: 9240876

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori positive diabetic subjects
Number of subjects: 69

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Diabetic subjects with anti-cow's milk protein positivity
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Diabetic subjects studied within 3 months of diabetes onset
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Diabetic subjects with asymptomatic Helicobacter pylori infection
Number of subjects: 69
Study: 8214664

Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg/kg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Atracurium 0.3 mg/kg
Number of subjects: 21
Study: 3610017

Group type: EXPERIMENTAL
Intervention: MDL 646 (800-1000 mcg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MDL 646 (500 mcg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29961438

Group type: EXPERIMENTAL
Intervention: Basal lamella relaxing incision
Number of subjects: 32

Group type: COMPARATOR
Intervention: Combined conventional medialisation and controlled synechiae
Number of subjects: 32
Study: 28162913

Group type: EXPERIMENTAL
Intervention: Coach-led preventive training program (PTP)
Number of subjects: 89
Study: 25945112

Group type: EXPERIMENTAL
Intervention: Structural Integration (SI) plus outpatient rehabilitation (OR)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Outpatient rehabilitation (OR) alone
Number of subjects: 46
Study: 23834406

Group type: EXPERIMENTAL
Intervention: Hypnosis + CD (hypnotherapist guided)
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: CD only (nurse administered)
Number of subjects: 448

Group type: COMPARATOR
Intervention: Control (no additional intervention or CDs)
Number of subjects: 448
Study: 20642944

Group type: EXPERIMENTAL
Intervention: Cool phacoemulsification technique
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional phacoemulsification technique
Number of subjects: 100
Study: 19060515

Group type: EXPERIMENTAL
Intervention: hylan G‐F 20 (Synvisc), 2 ml, three intra-articular injections
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: sodium hyaluronate (Hyalgan), 2 ml, five intra-articular injections
Number of subjects: 45

Group type: COMPARATOR
Intervention: No injections (controls)
Number of subjects: 45
Study: 16903964

Group type: EXPERIMENTAL
Intervention: Atrial shock conversion efficacy for spontaneous AT/AF episodes
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Atrial shock conversion efficacy for induced AT/AF episodes
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Mean detection time with new features ON
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Mean detection time with new features OFF
Number of subjects: 95

Group type: COMPARATOR
Intervention: Randomized crossover trial of atrial preventative pacing features
Number of subjects: 95
Study: 14528774

Group type: EXPERIMENTAL
Intervention: Laser alone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Laser followed by etching
Number of subjects: 60
Study: 11004650

Group type: EXPERIMENTAL
Intervention: C1‐2 high‐velocity, low‐amplitude manipulation
Number of subjects: 13
Study: 8977237

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) plus stem cell factor (SCF)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Flk-2/Flt3 ligand (FL) plus IL-3
Number of subjects: 26
Study: 1613122

Group type: EXPERIMENTAL
Intervention: Aspirin 1 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin 5 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin 15 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no aspirin)
Number of subjects: 0
Study: 6690170

Group type: EXPERIMENTAL
Intervention: Oral nalbuphine, 15 mg (N = 39)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Codeine, 60 mg (N = 42)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo (N = 40)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Oral nalbuphine (N = 39)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Codeine (N = 42)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Both active drugs
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: New parameters
Number of subjects: 121
Study: 31899888

Group type: EXPERIMENTAL
Intervention: Aerobic exercise + 12.5% energy intake reduction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 29523129

Group type: EXPERIMENTAL
Intervention: Educational video-assisted informed consent
Number of subjects: 142

Group type: COMPARATOR
Intervention: Conventional informed consent (reading an informed consent document)
Number of subjects: 142
Study: 26350171

Group type: EXPERIMENTAL
Intervention: Alendronate for 10 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (6 annual infusions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuation of oral BP treatment for up to 10 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuation of intravenous BP treatment for up to 6 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Drug holiday of 2 to 3 years after 3 to 5 years of BP treatment
Number of subjects: 0
Study: 24477080

Group type: EXPERIMENTAL
Intervention: Continued use of tiotropium, salmeterol, and fluticasone
Number of subjects: 2456

Group type: COMPARATOR
Intervention: Stepwise withdrawal of fluticasone
Number of subjects: 2456

Group type: EXPERIMENTAL
Intervention: Both groups (ICS and withdrawal)
Number of subjects: 2456
Study: 22252366

Group type: EXPERIMENTAL
Intervention: 10 mg vitamin E in crude soybean oil diet
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Oregano essential oil in crude soybean oil diet
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: 100 mg vitamin E in crude soybean oil diet
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Oregano essential oil in acidulated soybean oil soapstock diet
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: 10 mg vitamin E in acidulated soybean oil soapstock diet
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: 100 mg vitamin E in acidulated soybean oil soapstock diet
Number of subjects: 480
Study: 20844469

Group type: EXPERIMENTAL
Intervention: KTR (Kidney Transplant Recipients)
Number of subjects: 106

Group type: COMPARATOR
Intervention: CP (Control Patients)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: KTR treated with or without calcineurin inhibitors
Number of subjects: 106
Study: 19171954

Group type: EXPERIMENTAL
Intervention: Concept II model C (IIC) rowing ergometer
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Concept II model D (IID) rowing ergometer
Number of subjects: 8
Study: 16047526

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 102
Study: 12196460

Group type: EXPERIMENTAL
Intervention: Troglitazone (200 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 11767274

Group type: EXPERIMENTAL
Intervention: Burnout intervention program (19 participants)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control group (73 dentists)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control group (not taking preventive action)
Number of subjects: 171
Study: 9278803

Group type: EXPERIMENTAL
Intervention: Ketamine 0.3 mg/kg, droperidol 0.03 mg/kg, diazepam 0.06 mg/kg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (same drugs except for ketamine)
Number of subjects: 80
Study: 8444625

Group type: EXPERIMENTAL
Intervention: Educational program designed to reduce low back injuries, taught by physical therapists for 3 hours, with reinforcement every 6 months.
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Experimental unit workers who received training.
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Control group (untrained experimental unit workers).
Number of subjects: 4000
Study: 3541426

Group type: EXPERIMENTAL
Intervention: ID-1 group (3 doses of 0.1 ml intradermally at 0, 1 month, and 4 months)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: ID-2 group (2 doses of 0.2 ml intradermally at 0 and 1 dose of 0.1 ml at 4 months)
Number of subjects: 63

Group type: COMPARATOR
Intervention: IM group (3 doses of 1.0 ml intramuscularly at 0, 1 month, and 4 months)
Number of subjects: 63
Study: 28474871

Group type: EXPERIMENTAL
Intervention: Hydrogen rich water (HRW)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo normal water (PLA)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Both conditions (HRW and PLA)
Number of subjects: 8
Study: 27209463

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (counselling on diet, physical activity, and weight control)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Standard antenatal care (control group)
Number of subjects: 226
Study: 24817694

Group type: EXPERIMENTAL
Intervention: Mobile phone delivered intervention (HEART; n = 85) plus usual care
Number of subjects: 171

Group type: COMPARATOR
Intervention: Usual care alone (n = 86)
Number of subjects: 171
Study: 23975447

Group type: EXPERIMENTAL
Intervention: Amicar
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (No Amicar)
Number of subjects: 33
Study: 20873604

Group type: EXPERIMENTAL
Intervention: Modified Bazhengsan
Number of subjects: 72

Group type: COMPARATOR
Intervention: Primal Bazhengsan (Control)
Number of subjects: 72
Study: 18254432

Group type: EXPERIMENTAL
Intervention: Education training
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Education only
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control
Number of subjects: 51
Study: 16798860

Group type: EXPERIMENTAL
Intervention: Enamel specimens with pellicle after 10-minute erosive challenge
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dentin specimens with pellicle
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no pellicle)
Number of subjects: 0
Study: 13129692

Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study: 10958810

Group type: EXPERIMENTAL
Intervention: Zinc supplementation at 15 mg (RDA)
Number of subjects: 16
Study: 8968481

Group type: EXPERIMENTAL
Intervention: Outdoor exercise for about 5 hours on day 3
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (remained in rooms and went shopping)
Number of subjects: 10
Study: 1457117

Group type: EXPERIMENTAL
Intervention: Ketorolac 1 mg/kg IV up to 60 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Fentanyl 3 micrograms/kg IV up to 250 micrograms
Number of subjects: 80
Study: 29940986

Group type: EXPERIMENTAL
Intervention: Pushrim-activated power-assisted wheelchair (PAPAW)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Regular handrim wheelchair (RHW)
Number of subjects: 24
Study: 27769601

Group type: EXPERIMENTAL
Intervention: EVERA device
Number of subjects: 34

Group type: COMPARATOR
Intervention: AESTES device
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study: 24942631

Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic partial pleurectomy (VAT-PP)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Talc pleurodesis
Number of subjects: 196
Study: 23380743

Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dasatinib
Number of subjects: 0
Study: 21243762

Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg, 3 times a week
Number of subjects: 188
Study: 18954630

Group type: EXPERIMENTAL
Intervention: Atrial synchronous biventricular pacing
Number of subjects: 40

Group type: COMPARATOR
Intervention: Atrial inhibited pacing
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Atrial synchronous right ventricular pacing
Number of subjects: 40
Study: 15718044

Group type: EXPERIMENTAL
Intervention: Alzheimer's disease patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 0

Group type: COMPARATOR
Intervention: Young adults controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) stimulation
Number of subjects: 0
Study: 12953086

Group type: EXPERIMENTAL
Intervention: Paclitaxel plus cisplatin (PT)
Number of subjects: 798

Group type: COMPARATOR
Intervention: Paclitaxel plus carboplatin (TC)
Number of subjects: 798
Study: 10853413

Group type: EXPERIMENTAL
Intervention: Doxorubicin
Number of subjects: 349

Group type: COMPARATOR
Intervention: CMF
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Cardioxane treatment
Number of subjects: 349
Study: 8898643

Group type: EXPERIMENTAL
Intervention: Terlipressin (2 mg/4 h)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Somatostatin (continuous infusion of 250 micrograms/h after an intravenous injection of 250 micrograms)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 161

Group type: COMPARATOR
Intervention: Somatostatin
Number of subjects: 161
Study: 1847706

Group type: EXPERIMENTAL
Intervention: Sinorphan 100 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sinorphan 30 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 6391877

Group type: COMPARATOR
Intervention: Traditional calorically defined exchange‐type diet (EXCH)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Unmeasured diet emphasizing avoidance of refined sugar and balance of food consumption throughout the day
Number of subjects: 51
Study: 31303706

Group type: EXPERIMENTAL
Intervention: Palonosetron (1 mcg/kg, max 75 mcg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ondansetron (0.1 mg/kg, max 8 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Palonosetron
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ondansetron
Number of subjects: 100
Study: 30267340

Group type: EXPERIMENTAL
Intervention: ClearSight™ system (Edwards Lifesciences)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (oscillometric blood pressure monitoring)
Number of subjects: 40
Study: 26908434

Group type: EXPERIMENTAL
Intervention: JC seropositivity prior to diagnosis
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Increasing quartiles of JC seroreactivity
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Increasing quartiles of BK seroreactivity
Number of subjects: 342

Group type: COMPARATOR
Intervention: BK and JC seroreactivity stability
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Seroconversion following SCC diagnosis
Number of subjects: 342
Study: 24994839

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (low-dose)
Number of subjects: 4684

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4684
Study: 22545823

Group type: EXPERIMENTAL
Intervention: Resilience training program (formerly Battlemind training)
Number of subjects: 782
Study: 21171982

Group type: EXPERIMENTAL
Intervention: Two-dose schedule of hepatitis B vaccine
Number of subjects: 234

Group type: COMPARATOR
Intervention: Three-dose schedule of hepatitis B vaccine
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Challenge dose of hepatitis B vaccine
Number of subjects: 234
Study: 16846342

Group type: EXPERIMENTAL
Intervention: beta‐TCP + 1.0 mg/mL of recombinant human PDGF‐BB (rhPDGF‐BB)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: beta‐TCP carrier alone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: beta‐TCP + 0.3 mg/mL of rhPDGF‐BB
Number of subjects: 16
Study: 12630351

Group type: EXPERIMENTAL
Intervention: Polycomponent vaccine B[symbol: see text]‐4 by intranasal‐subcutaneous method
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Polycomponent vaccine B[symbol: see text]‐4 by intranasal oral method
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 10853303

Group type: EXPERIMENTAL
Intervention: Tendency Oriented Perimetry (TOP)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Frequency Doubling Perimetry (FDP)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Glaucoma Diagnostic (GDx)
Number of subjects: 38
Study: 9114644

Group type: EXPERIMENTAL
Intervention: Culturally and developmentally sensitive family intervention program
Number of subjects: 0
Study: 8251287

Group type: EXPERIMENTAL
Intervention: Trinitroglycerin (TNG)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Trinitroglycerin (TNG) and Isosorbide dinitrate (ISDN)
Number of subjects: 16
Study: 2579938

Group type: EXPERIMENTAL
Intervention: 40 Gy split course
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: 30 Gy continuous course
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: 40 Gy continuous course
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Cytoxan
Number of subjects: 409

Group type: COMPARATOR
Intervention: No further therapy following irradiation
Number of subjects: 409
Study: 31596961

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors
Number of subjects: 36472

Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 36472

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 36472
Study: 31851348

Group type: EXPERIMENTAL
Intervention: Decision support with the Child Health Improvement Through Computer Automation system (CHICA) in intervention clinics.
Number of subjects: 274

Group type: COMPARATOR
Intervention: Control clinics without the CHICA intervention.
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: CHICA screening results.
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Intervention group.
Number of subjects: 274
Study: 28335729

Group type: EXPERIMENTAL
Intervention: 5 weeks of training with an oral screen for neuromuscular training focused on orofacial and pharyngeal muscles
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 400
Study: 25774595

Group type: EXPERIMENTAL
Intervention: Risk model incorporating donor IL6 (rs1800797) and IFNG (rs2069727) genotypes and gastrointestinal involvement
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Risk model predictive effect in validation set
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Risk model association with response to therapy, overall and GVHD-specific survival and non-relapse mortality
Number of subjects: 268
Study: 23547564

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 22152644

Group type: EXPERIMENTAL
Intervention: Boston Psychiatric Rehabilitation (PR) Approach
Number of subjects: 156

Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 156
Study: 19374150

Group type: EXPERIMENTAL
Intervention: Healthy older adults swallowing thin liquids (milk, water, barium)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Healthy older adults swallowing various bolus types (5 or 10 mL)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Healthy older adults swallowing thin liquids compared to puree or solids
Number of subjects: 20
Study: 17988533

Group type: EXPERIMENTAL
Intervention: Oxymatrine (600 mg, intravenous drip, once a day for 7 days)
Number of subjects: 418

Group type: COMPARATOR
Intervention: Traditional equilibrium salt treatment (control group)
Number of subjects: 418
Study: 15247730

Group type: EXPERIMENTAL
Intervention: Sacred Heart Halo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Sur-Catch NT
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Halo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Vantage
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Zerotip
Number of subjects: 6
Study: 12495801

Group type: EXPERIMENTAL
Intervention: Case management condition 1
Number of subjects: 1063

Group type: EXPERIMENTAL
Intervention: Case management condition 2
Number of subjects: 1063

Group type: COMPARATOR
Intervention: Not applicable (control group not specified)
Number of subjects: 1063
Study: 9400460

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% (10 ml)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 40